Journal Article10.1007/S10147-017-1235-6
Efficacy of docetaxel in castration-resistant prostate cancer patients with intraductal carcinoma of the prostate.
Akiyuki Yamamoto,Masashi Kato,Hirotaka Matsui,Ryo Ishida,Tohru Kimura,Yasuhito Funahashi,Naoto Sassa,Yoshihisa Matsukawa,Osamu Kamihira,Ryohei Hattori,Momokazu Gotoh,Toyonori Tsuzuki +11 more
21
TL;DR: The presence of IDC-P is an independent prognostic factor in CRPC patients with distant metastases and IDC -P in needle biopsies at the time of initial diagnosis, and docetaxel may prolong CSS and OS.
read more
Abstract: This study aimed to investigate the efficacy of docetaxel in castration-resistant prostate cancer (CRPC) patients with intraductal carcinoma of the prostate (IDC-P). We retrospectively identified 79 CRPC patients with distant metastasis at initial diagnosis from June 2002 to January 2014. All patients received initial androgen deprivation therapy and 46 received docetaxel chemotherapy after progressing to CRPC. The primary outcome of interest was cancer-specific survival (CSS) from the time of CRPC diagnosis. The Cox regression model was used to confirm whether IDC-P and docetaxel would act as independent factors for prognosis. IDC-P was found in 62 of 79 patients. The median CSS in the IDC-P-present group was 18.2 versus 45.6 months in the IDC-P-absent group (HR 2.67; 95% CI 1.18 to 6.06; P = 0.019). Docetaxel was administered to 36 patients with IDC-P and 10 patients without IDC-P, with a median CSS of 20.5 versus 53.2 months, respectively (HR 2.98; 95% CI 1.02 to 8.64; P = 0.044). Multivariate analysis demonstrated that the presence of IDC-P and docetaxel were independent prognostic factors for CSS (P = 0.026 and 0.005, respectively) and overall survival (OS) (P = 0.029 and 0.001, respectively). The presence of IDC-P is an independent prognostic factor in CRPC patients with distant metastases and IDC-P in needle biopsies at the time of initial diagnosis. Docetaxel may prolong CSS and OS in CRPC patients with distant metastases and IDC-P in needle biopsies at the time of initial diagnosis.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
The 2019 genitourinary pathology society (GUPS) white paper on contemporary grading of prostate cancer
Jonathan I. Epstein,Jonathan I. Epstein,Mahul B. Amin,Mahul B. Amin,Samson W. Fine,Samson W. Fine,Ferran Algaba,Manju Aron,Manju Aron,Dilek Ertoy Baydar,Dilek Ertoy Baydar,Antonio Beltran,Antonio Beltran,Fadi Brimo,Fadi Brimo,John C. Cheville,John C. Cheville,Maurizio Colecchia,Maurizio Colecchia,Eva Compérat,Isabela Werneck da Cunha,Warick Delprado,Warick Delprado,Angelo M. DeMarzo,Angelo M. DeMarzo,Giovanna A. Giannico,Giovanna A. Giannico,Jennifer Gordetsky,Jennifer Gordetsky,Charles C. Guo,Charles C. Guo,Donna E. Hansel,Michelle S. Hirsch,Michelle S. Hirsch,Jiaoti Huang,Jiaoti Huang,Peter A. Humphrey,Peter A. Humphrey,Rafael E. Jimenez,Rafael E. Jimenez,Francesca Khani,Francesca Khani,Qingnuan Kong,Qingnuan Kong,Oleksandr N. Kryvenko,Oleksandr N. Kryvenko,L. Priya Kunju,L. Priya Kunju,Priti Lal,Mathieu Latour,Tamara L. Lotan,Fiona Maclean,Cristina Magi-Galluzzi,Rohit Mehra,Santosh Menon,Hiroshi Miyamoto,Rodolfo Montironi,Georges J Netto,Jane K. Nguyen,Adeboye O. Osunkoya,Anil V. Parwani,Brian D. Robinson,Mark A. Rubin,Rajal B. Shah,Jeffrey S. So,Hiroyuki Takahashi,Fabio Tavora,Maria S. Tretiakova,Lawrence D. True,Sara E. Wobker,Ximing J. Yang,Ximing J. Yang,Ming Zhou,Debra L. Zynger,Kiril Trpkov +74 more
TL;DR: Reactive stromal grade, percent GP4, minor tertiary GP5, and cribriform/intraductal carcinoma are not ready for adoption in current practice and molecular testing is reviewed.
216
Prostate cancer growth patterns beyond the Gleason score: entering a new era of comprehensive tumour grading.
TL;DR: Recent literature on the clinicopathological value and molecular characteristics of individual prostate cancer growth patterns, and how these, most particularly cribriform architecture, could alter treatment decisions for prostate cancer patients are summarized.
The Prognostic Impact of Intraductal Carcinoma of the Prostate: A Systematic Review and Meta-Analysis.
Noriyoshi Miura,Keiichiro Mori,Keiichiro Mori,Hadi Mostafaei,Hadi Mostafaei,Fahad Quhal,Fahad Quhal,Reza Sari Motlagh,Benjamin Pradere,Ekaterina Laukhtina,David D'Andrea,Takashi Saika,Shahrokh F. Shariat +12 more
TL;DR: ICD-P is a histopathological feature of biologically and clinically aggressive PCa that confers worse oncological outcomes in both localized and advanced PCa, whether assessed in biopsy or prostatectomy specimen.
33
Propensity score-matched comparison of docetaxel and androgen receptor axis-targeted agents in patients with castration-resistant intraductal carcinoma of the prostate.
Akiyuki Yamamoto,Masashi Kato,Kyosuke Hattori,Yushi Naito,Kosuke Tochigi,Tomoyasu Sano,Hideji Kawanishi,Tomohiro Ishikawa,Takuma Yuba,Ryohei Hattori,Momokazu Gotoh,Toyonori Tsuzuki +11 more
TL;DR: In this article, the efficacy of docetaxel and androgen receptor axis-targeted (ARAT) agents in patients with castration-resistant prostate cancer (CRPC) with intraductal carcinoma of the prostate (IDC-P) using a propensity score-matched analysis was evaluated.
16
The heterogeneity of intraductal carcinoma of the prostate is associated with different efficacy of standard first-line therapy for patients with metastatic castration-resistant prostate cancer
Zhipeng Wang,Sha Zhu,Jinge Zhao,Ling Nie,Xueqin Chen,Mengni Zhang,Ni Chen,Guangxi Sun,Junru Chen,Yuchao Ni,Jingdong Dai,Zhenhua Liu,Ronggui Tao,Xingming Zhang,Xudong Zhu,Haoran Zhang,Jiayu Liang,Zilin Wang,Ben He,Pengfei Shen,Hao Zeng +20 more
TL;DR: In this paper, the authors explore whether metastatic castration-resistant prostate cancer (mCRPC) patients with distinct intraductal carcinoma of the prostate (IDC-P) subtypes respond differently to abiraterone and docetaxel treatment.
References
Docetaxel plus Prednisone or Mitoxantrone plus Prednisone for Advanced Prostate Cancer
Ian F. Tannock,Ronald de Wit,William R. Berry,Jozsef Horti,Anna Pluzanska,Kim N. Chi,Stéphane Oudard,Christine Theodore,Nicholas D. James,Ingela Turesson,Mark Rosenthal,Mario A. Eisenberger +11 more
TL;DR: When given with prednisone, treatment with docetaxel every three weeks led to superior survival and improved rates of response in terms of pain, serum PSA level, and quality of life, as compared with mitoxantrone plusprednisone.
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer
Daniel P. Petrylak,Catherine M. Tangen,Maha Hussain,Primo N. Lara,Jeffrey A. Jones,Mary-Ellen Taplin,Patrick A. Burch,Donna L. Berry,Carol M. Moinpour,Manish Kohli,Mitchell C. Benson,Eric J. Small,Derek Raghavan,E. David Crawford +13 more
TL;DR: The improvement in median survival of nearly two months with docetaxel and estramustine, as compared with mitoxantrone and prednisone, provides support for this approach in men with metastatic, androgen-independent prostate cancer.
3.9K
The 2005 International Society of Urological Pathology (ISUP) consensus conference on Gleason grading of prostatic carcinoma
Geert J.L.H. van Leenders,Theodorus van der Kwast,David J. Grignon,Andrew Evans,Glen Kristiansen,Charlotte F. Kweldam,Geert Litjens,Jesse K. McKenney,Jonathan Melamed,N. Mottet,Gladell P. Paner,Hemamali Samaratunga,Ivo G. Schoots,Jeffry P. Simko,Toyonori Tsuzuki,Murali Varma,Anne Y. Warren,Thomas M. Wheeler,Sean R. Williamson,Kenneth A. Iczkowski +19 more
TL;DR: This manuscript summarizes the proceedings of the ISUP consensus meeting for grading of prostatic carcinoma held in September 2019, in Nice, France, where topics brought to consensus included approaches to reporting of Gleason patterns 4 and 5 quantities, and minor/tertiary patterns.
The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System.
Jonathan I. Epstein,Lars Egevad,Mahul B. Amin,Brett Delahunt,John R. Srigley,Peter A. Humphrey +5 more
TL;DR: The basis for a new grading system was proposed in 2013 by one of the authors and accepted by the World Health Organization for the 2016 edition of Pathology and Genetics: Tumours of the Urinary System and Male Genital Organs.
2.8K